Red Light Holland Engages Kala Bio’s Researgency.AI Platform to Support Clinical Development of Filament’s Patented PEX010 Botanical Psilocybin Drug Candidate

Rhea-AI Summary

Red Light Holland (CSE: TRIP; FSE: 4YX; OTCQB: TRUFF) engaged Kala Bio's Researgency.ai platform to support clinical development of PEX010, Filament’s patented botanical psilocybin drug candidate. The engagement will deploy agentic AI for clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 following a definitive arrangement to acquire Filament.

PEX010 is supplied to >70 clinical sites, has Health Canada and FDA trial authorizations, and showed positive Phase 2 data in alcohol use disorder; Kala holds exclusive worldwide distribution/development license for Researgency.ai.

Positive

• Definitive arrangement to acquire Filament’s business and IP portfolio (76 issued patents across 15 families)
• Deployment of Kala Bio’s Researgency.ai to support PEX010 clinical planning and protocol optimization
• PEX010 supplied to >70 clinical research sites worldwide
• PEX010 has Health Canada and FDA authorizations and positive Phase 2 data in alcohol use disorder

Negative

• None.

News Market Reaction – KALA

+0.16%

8 alerts

+0.16% News Effect

-12.4% Trough in 4 hr 28 min

+$367K Valuation Impact

$230M Market Cap

0.1x Rel. Volume

On the day this news was published, KALA gained 0.16%, reflecting a mild positive market reaction. Argus tracked a trough of -12.4% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $367K to the company's valuation, bringing the market cap to $230M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Issued patents: 76 issued patents Patent families: 15 patent families Registered resale shares: 241,435,910 shares +5 more

8 metrics

Issued patents 76 issued patents Filament portfolio related to botanical psilocybin

Patent families 15 patent families Filament intellectual property in botanical psilocybin

Registered resale shares 241,435,910 shares Resale registration on S-3 for existing stockholders

Preferred conversion shares 238,335,910 shares Shares from preferred stock conversions in S-3

Shares outstanding 911,330,225 shares Common shares outstanding as of Feb 4, 2026

Initial AI license cash $530,000 Cash payable to Younet during initial Researgency term

Younet share issuance 5,000,000 shares KALA common stock to be issued to Younet in AI deal

Younet acquisition option $55,000,000 Option price to acquire all Younet equity or assets

Market Reality Check

Price: $0.2525 Vol: Volume 6,682,022 is below...

low vol

$0.2525 Last Close

Volume Volume 6,682,022 is below the 20-day average of 17,496,437 (relative volume 0.38). low

Technical Trading below 200-day MA of 4.03, with shares near the 52-week low of 0.2325 and far below the 20.6 high.

Peers on Argus

KALA was down 5.37% while biotech peers showed mixed moves: BMEA (-3.94%), EQ (-...

1 Up

KALA was down 5.37% while biotech peers showed mixed moves: BMEA (-3.94%), EQ (-6.52%), IKT (-0.66%) declined, whereas CRBP (+0.73%) and TARA (+0.74%) rose. Momentum scanner only flagged FATE (+5.7%) higher, suggesting the move was stock-specific rather than a coordinated sector rotation.

Historical Context

5 past events · Latest: Mar 11 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 11	AI platform launch	Positive	+24.2%	Launch of Researgency.ai enterprise AI platform and first commercial agent timeline.
Mar 04	AI license deal	Positive	-1.5%	Exclusive license and development agreement for Researgency AI infrastructure platform.
Jan 05	Debt settlement	Positive	+6.9%	Settlement of approximately $10.6M of debt and added strategic flexibility.
Dec 05	Equity offering close	Negative	-6.6%	Closing of $10M registered direct offering of common stock at-the-market.
Dec 04	Equity offering announce	Negative	+4.2%	Announcement of $10M registered direct equity financing to repay indebtedness.

Pattern Detected

KALA’s news flow has centered on AI platform strategy, financings, and balance sheet actions, with mixed price alignment: three past events moved in the expected direction and two diverged, showing inconsistent but sometimes strong reactions to strategic updates.

Recent Company History

Over the last few months, KALA has shifted from a traditional biotech toward an AI-enabled model. On Dec 4–5, 2025, the company raised approximately $10 million through a registered direct offering, followed by a debt settlement of about $10.6 million announced on Jan 5, 2026. In March 2026, KALA secured an exclusive license to the Researgency AI platform and highlighted a potential $180+ billion AI-in-healthcare market. Today’s collaboration with Red Light Holland on PEX010 builds on that AI platform commercialization strategy.

Regulatory & Risk Context

Active S-3 Shelf

Shelf Active

Active S-3 Shelf Registration 2026-02-09

An effective S-3 shelf dated Feb 9, 2026 registers up to 241,435,910 existing-shareholder shares for resale, including 238,335,910 from preferred conversions. KALA will not receive proceeds from these sales but will cover registration expenses. The filing also reiterates Nasdaq notices that KALA is below market‑value and minimum bid‑price listing requirements, highlighting ongoing listing-risk overhang.

Market Pulse Summary

This announcement links KALA’s Researgency AI platform with Red Light Holland’s development of PEX01...

Analysis

This announcement links KALA’s Researgency AI platform with Red Light Holland’s development of PEX010, a widely studied botanical psilocybin candidate backed by 76 patents across 15 families. It reinforces KALA’s strategy to commercialize its AI infrastructure beyond its own pipeline. At the same time, a resale registration for up to 241,435,910 shares and Nasdaq minimum bid and market‑value deficiencies remain key backdrop risks to monitor alongside adoption of Researgency in external biotech programs.

Key Terms

psilocybin, Phase 2, clinical development, clinical trials

4 terms

psilocybin medical

"PEX010, the patented botanical psilocybin drug candidate originated by Filament Health"

A naturally occurring psychedelic compound found in certain mushrooms that alters perception, mood and consciousness; when taken the body converts it into an active substance that produces short-term hallucinogenic effects. Investors watch psilocybin because researchers and drug developers are exploring it as a potential treatment for depression, PTSD and other mental health conditions, so clinical trial results, regulatory decisions and changing stigma can create large commercial opportunities or risks—think of it as a new drug category whose approval pathway can drive big swings in company value.

Phase 2 medical

"has demonstrated positive Phase 2 clinical data in alcohol use disorder"

Phase 2 is the mid-stage clinical trial where a new drug or treatment is tested in a larger group of patients to see if it works and to keep checking safety after initial human testing. Think of it as a field test that proves whether a product actually delivers its promised benefit. Investors watch Phase 2 closely because its results strongly influence a medicine’s chances of reaching the market, the size of its potential sales, and the company’s valuation.

clinical development medical

"to support the clinical development strategy for PEX010"

Clinical development is the process of testing a medical treatment in people to prove it is safe and works, moving from small early safety checks to larger trials that measure benefit and side effects. For investors it matters because each successful step reduces uncertainty and brings a product closer to regulatory approval and sales—like moving a prototype through road tests before mass production—while failures or delays can dramatically cut expected value.

clinical trials medical

"received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials"

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

AI-generated analysis. Not financial advice.

• AI-powered autonomous research agents to be deployed in support of PEX010 clinical development strategy, leveraging Kala Bio’s purpose-built agentic AI platform for the biotechnology industry
  

TORONTO and ARLINGTON, Mass., March 18, 2026 (GLOBE NEWSWIRE) -- Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) (“Red Light” or the “Company”) and Kala Bio, Inc. (NASDAQ: KALA) (“Kala Bio”) today announced that Red Light has engaged Kala Bio’s with its Researgency.ai agentic artificial intelligence platform under world wide license from Younet to support the clinical development strategy for PEX010, the patented botanical psilocybin drug candidate originated by Filament Health Corp. (“Filament”). The engagement will deploy Kala Bio’s purpose-built AI research agents to assist in clinical planning, protocol optimization and scenario modeling as Red Light advances PEX010 through its regulated drug development program.

Red Light recently announced a definitive arrangement agreement to acquire Filament’s business, including its portfolio of 76 issued patents across 15 patent families, representing one of the largest intellectual property portfolios in botanical psilocybin drug development, as well as its lead drug candidate, PEX010.

Strategic Rationale

The engagement of the Kala’s Researgency.ai platform represents a key element of Red Light’s strategy to integrate advanced AI-driven research capabilities as it expands its regulated psychedelic drug development platform. By deploying custom purpose-built AI agents trained by Younet engineers in collaboration with Kala and under private cloud LLM infrastructure (supplied by Kala), Red Light intends to accelerate and enhance research planning, scenario simulation, and protocol optimization processes associated with advancing PEX010 through its clinical development program.

PEX010 is Filament’s patented botanical psilocybin drug candidate and is currently supplied to more than 70 clinical research sites worldwide, making it one of the most widely studied botanical psilocybin drug candidates in regulated clinical research. PEX010 is being studied across multiple indications, including alcohol use disorder, methamphetamine use disorder, treatment-resistant depression, cancer-related anxiety and depression, and cannabis use disorder, at leading research institutions including Johns Hopkins University and Dana-Farber Cancer Institute, among others. These indications represent areas of growing clinical and commercial momentum, with programs from Compass Pathways and AtaiBeckley also advancing psilocybin and psychedelic candidates toward late-stage regulatory milestones, and Johnson & Johnson’s Spravato continuing to demonstrate strong commercial traction in treatment-resistant depression.

The drug candidate has received both Health Canada and U.S. Food and Drug Administration authorization for clinical trials and has demonstrated positive Phase 2 clinical data in alcohol use disorder.

Researgency.ai is an agentic AI platform developed by Younet.ai with exclusive worldwide distribution/development license owned by Kala Bio, designed to deploy secure, on-premises AI agents purpose-built for biotechnology and pharmaceutical R&D workflows. The platform enables autonomous research loops capable of generating, simulating, and optimizing study scenarios at scale — compressing timelines and expanding the number of viable options considered before execution. The approach mirrors a broader industry shift toward purpose-built AI infrastructure for drug development, an area where NVIDIA and Eli Lilly have also committed significant resources through dedicated computing partnerships and in-house platforms.

Management Commentary

“As we move to integrate Filament’s exceptional clinical assets and intellectual property, engaging Kala Bio’s Researgency.ai platform is a natural next step in building a best-in-class psychedelic drug development operation,” said Todd Shapiro, Chief Executive Officer and Director of Red Light Holland. “PEX010 is already one of the most widely studied botanical psilocybin drug candidates in the world. By applying autonomous AI-driven research capabilities to our clinical development planning, we believe we can accelerate timelines, strengthen study designs, and make smarter, faster decisions across PEX010’s extensive clinical program.”

“Filament’s focus from the beginning has been to build a strong scientific and intellectual property foundation for botanical psilocybin drug development,” said Ben Lightburn, Chief Executive Officer of Filament Health Corp. “With PEX010 already supporting a growing body of global clinical research, the application of advanced analytical tools such as Kala Bio’s Researgency.ai platform has the potential to further strengthen how clinical development strategies are evaluated as the program continues to evolve.”

“Red Light’s decision to deploy Researgency.ai in support of PEX010 underscores exactly the kind of high-value, data-intensive challenge our platform was built to address,” said Avi Minkowitz, Chief Executive Officer of Kala Bio. “Psychedelic drug development is a complex, rapidly evolving field where the ability to quickly simulate and evaluate clinical scenarios can make a meaningful difference. We are excited to work with the Red Light team as they advance one of the leading botanical psilocybin programs in the world.”

About Researgency.ai

Researgency.ai is an agentic AI platform under worldwide distribution/development license by Kala Bio Inc. (NASDAQ: KALA) launched by Younet.ai, designed to bring autonomous research-agent workflows to biotechnology R&D planning. The platform deploys purpose-built AI agents that can simulate scenarios, optimize protocols, and support evidence-driven decisions in a secure, on-premises environment built for pharmaceutical-grade compliance. For more information, visit www.Researgency.ai.

About PEX010

PEX010 is a patented botanical psilocybin drug candidate developed by Filament Health Corp. PEX010 is formulated as a capsule for oral administration and is protected by Filament’s portfolio of 76 issued patents across 15 patent families covering natural psilocybin extraction, purification, standardization, stabilization, and alternative delivery formulations. PEX010 is currently supplied to more than 70 clinical research sites worldwide and is being studied in multiple Health Canada and FDA-authorized clinical trials across a range of mental health indications.

About Red Light Holland

Red Light Holland Corp. (CSE: TRIP) (FSE: 4YX) (OTCQB: TRUFF) is a Toronto-based company advancing a focused strategy within the legal psychedelic sector, centered on voluntary data collection and R&D initiatives designed to expand naturally occurring drug development and understanding of psilocybin use and consumer experiences. The Company operates commercial activities across Europe and North America, including psilocybin truffle sales in the Netherlands’ legal market and mushroom home grow kits offered through B2B and DTC channels, in compliance with applicable laws. Red Light has entered into a definitive arrangement agreement to acquire Filament Health Corp., which is expected to expand the Company’s drug development platform with GMP manufacturing capabilities, comprehensive Health Canada licensing, FDA-authorized clinical programs, and a portfolio of 76 issued patents. For more information, visit www.RedLight.co.

About Filament Health

Filament Health is a clinical-stage natural psychedelic drug development company. Filament believes that safe, standardized, naturally-derived psychedelic medicines can improve the lives of many, and its mission is to see them in the hands of everyone who needs them as soon as possible. Filament's platform of proprietary intellectual property enables the discovery, development, and delivery of natural psychedelic medicines for clinical development. Filament is paving the way with the first-ever natural psychedelic drug candidates. 

About Kala Bio, Inc.

Kala Bio, Inc. (NASDAQ: KALA) is a clinical-stage biopharmaceutical company building a dedicated, on-premises AI infrastructure platform for the biotechnology industry. The Company’s dual strategy combines a proprietary biologics pipeline, including its mesenchymal stem cell secretome (MSC-S) platform and FDA Orphan Drug and Fast Track designated product candidates, with a scalable AI platform-as-a-service business designed to deploy secure, purpose-built AI systems directly within biotech and pharmaceutical client environments. Through its exclusive worldwide license for the Researgency AI research platform from Younet, Kala intends to serve as the dedicated AI infrastructure partner for the biotechnology industry. For more information, visit www.kalarx.com.

For additional information on Red Light Holland:

Todd Shapiro 
Chief Executive Officer & Director 
Tel: 647-204-7129 
Email: todd@redlight.co 
Website: www.RedLight.co

For additional information on Filament:

Benjamin Lightburn
Chief Executive Officer & Director 
Email: ben@filament.health
Website: www.filament.health

For additional information on Kala Bio, Inc.:

Kala Bio, Inc.
Avi Minkowitz
Chief Executive Officer
Email: am@kalarx.com
Website: www.kalarx.com
www.Researgency.ai

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian and United States securities legislation, including statements regarding the expected benefits and applications of the Researgency.ai platform in connection with PEX010 and Red Light’s drug development programs; the anticipated impact of AI-driven research tools on clinical development timelines and decision-making; the expected completion of Red Light’s acquisition of Filament; and the future development and commercialization of PEX010. Forward-looking statements are based on management’s current expectations and assumptions and are subject to risks and uncertainties that could cause actual results to differ materially, including, among others: the ability to develop, deploy, and integrate new AI technologies; the performance and reliability of AI models and simulations; data availability and quality; cybersecurity and privacy considerations; the regulatory environment for psychedelic substances and AI-driven tools in Canada, the United States, and internationally; the ability to complete the acquisition of Filament on the anticipated terms and timeline; the ability to realize the anticipated benefits of the Filament transaction; the ability to retain key personnel; risks inherent in clinical drug development; and other risks described in Red Light’s and Kala Bio’s respective public filings. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Neither Red Light nor Kala Bio undertakes any obligation to update any forward-looking statements to reflect events or circumstances after the date of this release, except as required by law.

FAQ

What does Kala Bio’s Researgency.ai engagement mean for PEX010 clinical development (KALA)?

It means Red Light will use autonomous AI agents to plan and optimize clinical studies for PEX010. According to Red Light, Researgency.ai will assist in protocol optimization, scenario modeling and accelerating research planning across the global PEX010 program.

How extensive is PEX010’s current clinical footprint for investors tracking KALA?

PEX010 is currently supplied to more than 70 clinical research sites worldwide. According to the companies, PEX010 is being studied across multiple indications at leading institutions including Johns Hopkins and Dana-Farber.

What intellectual property will Red Light acquire from Filament in the deal related to PEX010?

Red Light’s arrangement includes Filament’s portfolio of 76 issued patents across 15 patent families. According to the announcement, this represents a large botanical psilocybin IP portfolio tied to PEX010 and related assets.

What regulatory milestones has PEX010 achieved that matter to KALA investors?

PEX010 has received clinical trial authorizations from Health Canada and the U.S. FDA. According to the companies, PEX010 also demonstrated positive Phase 2 clinical data in alcohol use disorder, supporting its development program.

Will Kala Bio’s Researgency.ai deployment change Kala Bio’s role in PEX010 development (KALA)?

Kala Bio will provide the Researgency.ai platform under its exclusive license to support Red Light’s program. According to Kala Bio, the platform supplies on-premises AI agents and private cloud LLM infrastructure for research workflows.